Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The stress-activated protein kinase pathway, also known as the c-Jun N-terminal kinase (JNK) pathway or SAPK/JNK, is a major signaling cascade within the mitogen-activated protein kinase (MAPK) family. It is primarily activated in response to various cellular stresses and inflammatory cytokines. The core of this pathway consists of JNK proteins, and activation occurs through a hierarchical phosphorylation cascade involving MAP4Ks/MAP3Ks and MAP2Ks (MKK4/7). Once activated, SAPK/JNK regulates transcription factors such as c-Jun, orchestrating diverse cellular responses like proliferation, apoptosis, cell motility, metabolism, and DNA repair. Dysregulation of the pathway has been implicated in numerous diseases, including neurodegenerative disorders, chronic inflammation, and cancer, making it an attractive therapeutic target.
Pharmacological inhibition of JNK
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stress activated protein kinase pathway (SAPK/JNK) (SAPK/JNK).